Icariin Mitigated Non-Alcoholic Fatty Liver Disease Progression via miR-185-3P/CX3CL1 Axis
Rattachement africain : cn, hk. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Non-alcoholic fatty liver disease (NAFLD) ranks among the most prevalent liver diseases globally. Icariin (ICA) has been shown to improve NAFLD, but the specific molecular mechanisms remain unclear. The study was to probe the underlying mechanisms of ICA in NAFLD. Quantitative real-time PCR (RT-qPCR) was employed to detect gene levels. Enzyme-linked immunosorbent assay (ELISA) was utilized to measure the concentrations of inflammatory factors. The target-binding relationship was validated through a dual-luciferase reporter assay and RNA Immunoprecipitation (RIP) assay. Our findings revealed that ICA dose-dependently decreased the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C), while increasing high-density lipoprotein cholesterol (HDL-C) levels in the NAFLD model. Additionally, it dose-dependently reduced the levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-12 (IL-12), and elevated miR-185-3p expression. In free fatty acids (FFA)-treated HepG2 cells, the miR-185-3p inhibitor attenuated the suppressive effect of ICA on inflammatory factors and its promoting effect on miR-185-3p levels. Fractalkine (CX3CL1) levels were diminished in an ICA dose-dependent manner. In FFA-treated HepG2 cells, silencing miR-185-3p elevated the secretion of inflammatory factors, whereas si-CX3CL1 reversed this effect. ICA alleviated liver damage, lipid metabolism disorders, and inflammatory responses via the miR-185-3p/CX3CL1 axis, thereby slowing the progression of NAFLD.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Icariin Mitigated Non-Alcoholic Fatty Liver Disease Progression via miR-185-3P/CX3CL1 Axis
- Date Crossref
- 17/06/2026
- Éditeur
- Polish Pharmaceutical Society
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nanjing University of Chinese Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Jiangning District of Nanjing Chinese Medicine Hospital pays non établi dans la noticeÉtablissement de santé
-
Nanjing Jiangning Hospital Department of Integrated Traditional Chinese and Western Medicine pays non établi dans la noticeÉtablissement de santé
-
Nanjing Traditional Chinese Medicine Hospital pays non établi dans la noticeÉtablissement de santé
-
Integrated Chinese Medicine (China) pays non établi dans la noticeEntreprise
-
Nanjing Hospital Affiliated to Department of Integrated Traditional Chinese and Western Medicine pays non établi dans la noticeÉtablissement de santé
Nanjing University of Chinese Medicine, Jiangning District of Nanjing Chinese Medicine Hospital et Department of Integrated Traditional Chinese and Western Medicine — Nanjing Jiangning Hospital, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.